Trial
NCT02700841
Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Nebraska
Collaborators
—
Condition
Plasma Cell Myeloma
Intervention
Melphalan
Why stopped
Study terminated prematurely due to poor recruitment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-03-12